GE HealthCare (Nasdaq: GEHC) announced today that it entered into an agreement to acquire AI-powered imaging analysis company Icometrix.
Icometrix develops imaging analysis technology for neurological disorders such as Alzheimer’s disease. It aims to meet the growing demand for MRI in personalized treatment planning.
The deal remains subject to customary closing conditions, including regulatory approvals. The companies declined to disclose the financial details, but GE HealthCare plans to fund the deal with cash on hand.
GE HealthCare said its planned acquisition aligns with its precision care strategy. It expects the deal to strengthen its clinical decision support applications for timely diagnosis and monitoring through the neuro treatment pathways. The company’s current solutions enable holistic offerings for its customers, according to a news release.
“This effort marks a pivotal step in our journey to advance precision care in neurology,” said Roland Rott, president and CEO, Imaging at GE HealthCare. “By integrating icometrix’s AI-powered insights with our advanced imaging technologies, we aim to empower care teams with the clarity and confidence needed to navigate complex neurological conditions.”
More about Icometrix ahead of its acquisition by GE HealthCare
Belgium-based Icometrix’s suite of solutions includes tools that assist radiologists and neurologists with comparing and quantifying brain MR scans over time for disorders ranging from multiple sclerosis, dementia, epilepsy, stroke and traumatic brain injury, among others.
The company’s product suite also has a strong pipeline of clinical support applications in development to improve neurological care.
GE HealthCare said it plans to integrate the Icometrix Icobrain platform with its MRI platforms to enable seamless workflows. Icobrain Aria includes the first FDA-cleared computer-aided detection and diagnosis solution for detecting and quantifying known side effects of amyloid targeting therapies, known as amyloid-related imaging abnormalities (ARIA).
The company said it wants to focus on expanding patient access to the Icobrain Aria solution on all vendor MRI systems. Icometrix’s offering provides radiologists with tools for monitoring Alzheimer’s patients over the course of treatment.
“Building on our existing relationship, we are excited by the prospect of joining GE HealthCare and leveraging icometrix’ innovation talents and customer relationships to continue to improve the diagnostic and treatment journey for both neurological clinicians and their patients,” said Wim Van Hecke, Icometrix CEO. “Together, we aim to leverage our complementary technology to address the complexities of managing neurological care.”
